Integra Lifesciences Holdings (IART) Operating Leases (2019 - 2026)

Integra Lifesciences Holdings has disclosed Operating Leases across 8 years of filings, most recently posting $176.6 million for Q2 2026.

• In Q2 2026, Operating Leases rose 1.81% year-over-year to $176.6 million; the TTM figure through Jun 2026 stood at $176.6 million (up 1.81% YoY), while the FY2025 annual figure was $177.1 million, down 2.42% from the prior year.
• Operating Leases came in at $176.6 million for Q2 2026 at Integra Lifesciences Holdings, up from $174.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $186.4 million in Q1 2024 to a low of $102.1 million in Q1 2022.
• Average Operating Leases over 5 years is $172.7 million, with a median of $175.2 million recorded in 2025.
• Year-over-year, Operating Leases retreated 6.71% in 2022 and surged 68.16% in 2023.
• Over 5 years, Operating Leases stood at $172.0 million in 2022, then grew by 5.86% to $182.1 million in 2023, then slipped by 0.36% to $181.5 million in 2024, then slipped by 2.42% to $177.1 million in 2025, then declined by 0.28% to $176.6 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $176.6 million in Q2 2026, $174.0 million in Q1 2026, and $177.1 million in Q4 2025.